Morphine

證據等級: L5

預測適應症: 10 個

Morphine: From Pain Management to Myofascial Pain Syndrome

One-Sentence Summary

Morphine is a mu-opioid receptor agonist used clinically as an analgesic for moderate-to-severe pain across a wide range of conditions. The TxGNN model predicts it may be effective for Myofascial Pain Syndrome, with 33 clinical trials and 17 publications identified in the evidence search, though most are indirect (adjacent pain conditions) rather than trials designed specifically for this indication.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (regulatory license data unavailable — Data Gap DG001). Morphine is a globally established opioid analgesic for moderate-to-severe pain.
Predicted New Indication	Myofascial Pain Syndrome
TxGNN Prediction Score	99.75%
Evidence Level	L3
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in this evidence pack (Data Gap DG002). Based on established pharmacology, morphine is a mu-opioid receptor agonist used clinically for moderate-to-severe pain, including postoperative pain, cancer pain, and selected chronic non-cancer pain states.

Myofascial pain syndrome (MPS) is a chronic musculoskeletal pain condition driven by myofascial trigger points, producing localized and referred pain. Opioid analgesics, including morphine, are already used as adjunct or rescue therapy in adjacent chronic and postoperative pain contexts that overlap clinically with MPS — for example, intra-articular/local morphine infusion for TMJ-related myofascial pain, trigger-point-associated postoperative pain following knee/cervical surgery, and opioid-sparing strategies in chronic musculoskeletal pain trials.

Mechanistically, opioid receptors are present in both peripheral nociceptors and central pain-processing circuits implicated in trigger-point sensitization, which supports biological plausibility. However, the evidence base is indirect: no clinical trial or publication in this pack evaluates morphine specifically as a treatment for MPS as a primary endpoint — most evidence comes from related pain populations (TMJ dysfunction, post-thoracotomy pain, chronic low back pain, postsurgical myofascial pain). This is why the evidence level is L3 and the case remains at the “Research Question” stage rather than a stronger recommendation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07413770	NA	Recruiting	60	Evaluates classical massage, alone and combined with physiotherapy, on pain and function in myofascial pain syndrome
NCT05478928	NA	Unknown	60	Compares invasive techniques (percutaneous microelectrolysis, dry needling) for myofascial trigger points using pressure pain threshold
NCT04640896	Phase 4	Recruiting	60	Trigger point injections vs traditional therapies for postsurgical cervical myofascial pain after anterior cervical surgery
NCT06955923	Phase 2	Completed	11	Trigger point injections after total knee arthroplasty to reduce pain and opioid use vs sham injection
NCT03944889	Early Phase 1	Completed	20	Capsaicin-induced central sensitization model relevant to myofascial pain syndrome pathophysiology
NCT04504812	Phase 3	Completed	1937	Sequenced treatment strategy to reduce opioid reliance and improve outcomes in knee osteoarthritis pain
NCT03271151	Phase 4	Completed	160	Duloxetine’s effect on postoperative opioid use after total knee arthroplasty (opioid as comparator, not morphine-specific)
NCT04831346	NA	Recruiting	100	Low-level laser therapy vs occlusive splints for pain in temporomandibular disorders (myofascial component)
NCT03813485	NA	Unknown	24	EMG changes with dry needling of latent myofascial trigger points in the trapezius
NCT05069363	NA	Recruiting	20	Whole-body photobiomodulation feasibility trial for chronic pain, referencing morphine as a current standard therapy

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41664327	2026	RCT	Asian Spine Journal	Double-blind RCT comparing dexmedetomidine+morphine vs plain ropivacaine for myofascial infiltration in thoracolumbar spinal fusion
20390305	2010	Cohort	Schmerz	Altered pain thresholds during and after opioid withdrawal in chronic low back pain patients
21419546	2011	Review	J Oral Maxillofac Surg	Long-term opioid use in chronic temporomandibular joint dysfunction (myofascial-related)
16967674	2006	Review	J Calif Dent Assoc	Oral medications, infusions and injections for differential diagnosis of orofacial pain
35066974	2022	Cohort	Pain Practice	Structured stretching exercise program’s effect on resolving myofascial pain and opioid usage in “legacy pain” patients
22648287	2012	Clinical study	Journal of Anesthesia	Cervical facet joint injections added to multimodal treatment for long-standing cervical myofascial pain syndrome
16713811	2006	Clinical review	J Oral Maxillofac Surg	TMJ arthrocentesis followed by intra-articular morphine infusion for refractory TMJ pain
17870625	2008	RCT	European Journal of Pain	Epidural bupivacaine/morphine vs intercostal cryoanalgesia for post-thoracotomy pain control
39793344	2025	Clinical study	Eur J Obstet Gynecol Reprod Biol	Pudendal nerve block’s effect on perioperative pain following BTA injection for myofascial pelvic pain
21691691	2011	Descriptive study	Rev Assoc Med Bras	Therapeutic approach and follow-up in 56 patients with failed back surgery pain syndrome

US Market Information

No NDA or marketing authorization records were found in this evidence pack (0 licenses; market status: Not Marketed). Regulatory license data (brand names, dosage forms, approved indication text) is a documented data gap (DG001) and would need to be obtained directly from the relevant regulatory agency before further evaluation.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug-drug interaction data were not available in this evidence pack (Data Gap DG001, blocking severity — this prevents the case from entering S1 safety pre-assessment).

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence linking morphine to myofascial pain syndrome specifically is indirect (L3) — no trial or publication evaluates morphine as a primary treatment for MPS; the supporting evidence comes from adjacent conditions (TMJ dysfunction, post-thoracotomy pain, postsurgical trigger-point pain). Combined with a blocking safety data gap, this indication is not yet ready to advance past the research-question stage.

To proceed, the following is needed:

TFDA/regulatory label data — warnings, contraindications (Data Gap DG001, blocking)
Detailed mechanism-of-action documentation (Data Gap DG002)
An MPS-specific clinical trial or post-hoc analysis of morphine efficacy, rather than extrapolation from adjacent pain populations
Route-of-administration compatibility assessment (currently unassessed/pending)
Given morphine’s opioid class, a dependency/misuse risk-benefit analysis specific to a chronic, non-life-threatening pain condition like MPS
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.